国际皮肤性病学杂志    2007 33 (5): 317-319   ISSN: 2096-5540  CN: 32-1880/R   硬皮病动物模型的应用进展 鞠梅, 顾恒 中国医学科学院皮肤病研究所 南京 210042 收稿日期 2006-12-01  修回日期 null  网络版发布日期 null 参考文献  [1] Zhang Y,Gilliam AC.Animal models for scleroderma:an update.Curr Rheumatol Rep,2002,4 (2):150-162. [2] Yamamoto T,Takagawa S,Katayama I,et al.Animal model of sclerotic skin.Ⅰ:Local injections of blcomycin induce sclerotic skin mimicking scleroderma.J Invest Dermatol,1999,112 (4):456-462. [3] Yamamoto T,Kuroda M,Nishioka K.Animal model of sclerotic skin.Ⅲ:Histopathological comparison of bleomycin-induced scleroderma in various mice strains.Arch Dermatol Res,2000,292(11):535-541. [4] Gentiletti J,McCloskey LJ,Artlett CM,et al.Demonstration of autoimmunity in the fight skin-2 mouse:a model for scleroderma.J Immunol,2005,175 (4):2418-2426. [5] Chatterjee S,Mark ME,Wooley PH,et al.Increased dermal elastic fibers in the tight skin mouse.Clin Exp Rheumatol,2004,22 (5):617-620. [6] Baxter RM,Crowell TP,McCrann ME,et al.Analysis of the tight skin (Tsk1/+) mouse as a model for testing antifibrotic agents.Lab Invest,2005,85 (10):1199-1209. [7] Samuel CS,Zhao C,Yang Q,et al.The relaxin gene knockout mouse:a model of progressive scleroderma.J Invest Dermatol,2005,125 (4):692-699. [8] Ruzek MC,Jha S,Ledbetter S,et al.A modified model of g raft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease.Arthritis Rheum,2004,50 (4):1319-1331. [9] Yamamoto T.The bleomycin-induced scleroderma model:what have we learned for scleroderma pathogenesis? Arch Dermatol Res,2006,297 (8):333-344. [10] Wang HW,Tedla N,Hunt JE,et al.Mast cell accumulation and cytokine expression in the tight skin mouse model of scleroderma.Exp Dermatol,2005,14 (4):295-302. [11] Yamamoto T,Nishioka K.Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma.J Invest Dermatol,2004,122 (1):44-50. [12] Fujimoto M,Hamaguchi Y,Yazawa N,et al.Autoantibodies to a collagen-specific molecular chaperone,heat-shock protein 47,in systemic sclerosis.Clin Exp Immunol,2004,138 (3):534-539. [13] Matsushita M,Yamamoto T,Nishioka K.Upregulation of inter leukin-13 and its receptor in a murine model of bleomycin-induced scleroderma.Int Arch Allergy Immunol,2004,135 (4):348-356. [14] Shen Y,Ichino M,Nakazawa M,et al.CpG oligodeoxynucleotides prevent the development of scleroderma-like syndrome in tight-skin mice by stimulating a Th1 immune response.J Invest Dermatol,2005,124 (6):1141-148. [15] Santiago B,Gutierrez-Canas I,Dotor J,et al.Topical application of a peptide inhibitor of transforming growth factor-betal ameliorates bleomycin-induced skin fibrosis.J Invest Dermatol,2005,125 (3):450-455. [16] McGaha TL,Phelps RG,Spiera H,et al.Halofuginone,an inhibitor of type-Ⅰ collagen synthesis and skin sclerosis,blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.J Invest Dermatol,2002,118 (3):461-470. [17] Krause I,Shoenfeld Y.Intravenous immunoglobulin treatment for fibrosis,atherosclerosis,and malignant conditions.Methods Mol Med,2005,109:403-408. [18] Wu MH,Yokozeki H,Takagawa S,et al.Hepatocyte growth factor both prevents and ameliorates the symptoms of dermal sclerosis in a mouse model of scleroderma.Gene Ther,2004,11(2):170-180. 通讯作者: